• Ipsen raised its 2026 sales growth forecast to about 23% at constant exchange rates, from above 20%.
• The core operating margin target increased to about 39% of sales, from above 37%.
• Nine-month sales rose 24.6% at constant exchange rates to EUR 3.36 billion, supporting the upgraded outlook.
• Guidance assumes sustained double-digit strategic portfolio growth and rising Somatuline sales despite anticipated generic lanreotide entry in the fourth quarter.
• Foreign exchange is expected to reduce sales growth by about 0.5%, based on October exchange rates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220100OMX_____CNEWS_FR_GNW1001279204_fr) on October 22, 2026, and is solely responsible for the information contained therein.